Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly Revenues Down 11% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly Revenues Down 11% in the Quarter

Lack of COVID-19 antibodies sales impacts results, while growth products revenue increased 18% to $4.6 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
1Q Revenues: $7.0 billion (-11%) 
1Q Earnings: $1.3 billion (-29%) 
Comments: Decline in revenues was driven by a 5% decrease due to lower realized prices, a 4% decrease due to lower volume, and a 2% decrease from the unfavorable impact of foreign exchange rates. The decline was driven by $1.47 billion in revenue from COVID-19 antibodies in 1Q22, with sales in the quarter down 100%. New Products contributed $573.6 million to revenue in the quarter. Growth Products revenue increased 18% to $4.6 billion. R&D expenses increased 23% to $1.99 billion, or 29% of revenue, primarily driven by higher development expenses for late-stage assets.
 
Trulicity sales were up 14% to $1.97 billion. Verzenio sales were up 60% to $751 million. Jardiance sales were up 38% to $577.5 million. Mounjaro sales reached $568.5 million in the quarter. Mounjaro launched in the U.S. for the treatment of type 2 diabetes in June 2022.Taltz sales were up 8% to $527 million. Humalog sales were down 25% to $460.9 million. Cyramza sales were up 3% to $236.8 million. Olumiant sales were down 10% to $228.9 million. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters